news & events - latest news and happenings in the SCD community | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for Endari™ (L-glutamine oral powder)

Emmaus Life Sciences, Inc., announces it has entered into a distribution agreement with McKesson Plasma and Biologics LLC (McKesson), a division of McKesson Corporation. The agreement makes Endari™ (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, available nationwide to pharmacies that utilize McKesson as their primary and exclusive distributor. McKesson is the largest healthcare distribution company in the world.

Since launching Endari, the first U.S. FDA approved sickle cell treatment in 20 years, Emmaus has brought this therapy to patients in over 30 states, Washington DC and Puerto Rico. In addition to the distributors already in place, this agreement with McKesson will further broaden Endari’s distribution, with the potential to reach many more patients suffering from the acute complications associated with sickle cell disease.

“As the demand for Endari continues to increase, we seek to build our distribution network to ensure that we reach patients in need,” said Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus.

Aug 27, 2018

Annual management of Sickle cell disease conference 2018


The Sickle Cell Disease Association of Illinois (SCDAI’s) Annual Management of Sickle Cell Disease Conference is designed for nurses, health care professionals, providers, educators, social workers, students, individuals with sickle cell disease and their families and the community at large. The purpose of this educational activity is to strengthen participant’s knowledge base about sickle cell disease and sickle cell trait through lecture, discussion and sharing of current and future treatment regimen. 


Upon completion of this activity, participants should be able to:

• identify current evidence-based practices to improve care of individuals with Sickle Cell Disease

• discuss complications related to Sickle Cell Disease

• explain resources available to individuals with Sickle Cell



Friday, November 9, 2018 from 7:00 AM to 4:00 PM CDT



The Loretto Hospital 

645 S Central Ave, Chicago, IL, USA


Register Here

Nov 9, 2018